10-Q: SS Innovations Q3 2025: Revenue Soars, Net Loss Narrows

SS Innovations International, Inc. reports significant revenue growth and a reduced net loss for the first nine months of 2025, driven by increased surgical robotic system sales, despite ongoing operational losses and internal control weaknesses.

Summary

• Total revenue for the three months ended September 30, 2025, increased by 192.5% to $12,829,349, compared to $4,386,516 for the same period in 2024.
• Total revenue for the nine months ended September 30, 2025, increased by 123% to $27,950,264, compared to $12,533,335 for the same period in 2024.
• Gross profit for the three months ended September 30, 2025, was $6,164,936, a 166% increase from $2,317,407 in Q3 2024, attributed to decreased raw material prices and improved manufacturing processes.
• Gross profit for the nine months ended September 30, 2025, was $13,167,202, a 193.7% increase from $4,483,375 in the prior year period.
• Net loss for the three months ended September 30, 2025, was $(3,717,964), an increase from $(3,245,483) in Q3 2024, primarily due to the first-time recognition of income tax expense in Indian operations.
• Net loss for the nine months ended September 30, 2025, significantly decreased by 43.9% to $(9,656,008), from $(17,227,806) in the prior year period.
• The company sold 28 surgical robotic systems in Q3 2025 and 55 systems during the first nine months of 2025.
• A working capital surplus of $27,237,289 was reported as of September 30, 2025, but the company continues to operate on a 'going concern' basis due to historical losses and dependence on external funding.
• Material weaknesses in internal control over financial reporting were identified, including inadequate controls for U.S. GAAP application, lack of written documentation, and insufficient segregation of duties.

Sentiment

Score: 6

Explanation: While the company shows strong revenue and gross profit growth and a reduced nine-month net loss, the persistent 'going concern' warning, reliance on related-party financing, and identified material weaknesses in internal controls temper the overall positive sentiment. The Q3 net loss increase due to tax expense also adds a slight negative.

Positives

• Total revenue for Q3 2025 increased by 192.5% year-over-year to $12.83 million.
• Total revenue for the nine months ended September 30, 2025, increased by 123% year-over-year to $27.95 million.
• Gross profit for Q3 2025 increased by 166% to $6.16 million, driven by decreased raw material prices and improved manufacturing processes.
• Gross profit for the nine months ended September 30, 2025, increased by 193.7% to $13.17 million.
• Net loss for the nine months ended September 30, 2025, significantly decreased by 43.9% to $(9.66) million from $(17.23) million in the prior year period.
• The company successfully completed its uplisting to the Nasdaq Stock Market LLC (NASDAQ) in April 2025.
• A working capital surplus of $27,237,289 was reported as of September 30, 2025.

Negatives

• The company incurred a net loss of $(3,717,964) for Q3 2025, an increase from $(3,245,483) in Q3 2024, primarily due to the first-time recognition of income tax expense in Indian operations.
• Substantial doubt exists about the company's ability to continue as a going concern due to historical losses and dependence on related parties to fund operations.
• Material weaknesses in internal control over financial reporting were identified, including inadequate controls for U.S. GAAP application, lack of written documentation, and insufficient segregation of duties.
• Selling, general and administrative (SG&A) expenses increased significantly for both Q3 2025 ($4.82 million vs $2.51 million) and the nine months ended September 30, 2025 ($11.46 million vs $7.60 million), driven by higher legal/underwriting fees and business events.
• Net cash used in operating activities increased to $(17,023,417) for the nine months ended September 30, 2025, from $(6,241,269) in the prior year period.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to historical losses and dependence on external funding.
• There is no assurance that the company will be able to raise additional equity capital or be successful in generating additional revenues and ultimately achieving profitability.
• Failure to secure additional funding could force the company to curtail expansion plans, research and development, and marketing activities.
• Any successful additional financing could substantially dilute current stockholders.
• Material weaknesses in internal control over financial reporting could adversely affect the company's ability to record, process, summarize, and report financial information reliably.
• The company is subject to inherent uncertainties from various lawsuits and legal proceedings that arise in the ordinary course of business, which could harm the business.
• An ongoing appeal before the Income Tax Appellate Tribunal (ITAT) regarding a transfer pricing adjustment of $533,281 for the assessment year 2021-22 poses a contingent liability.

Future Outlook

The company plans to raise additional capital through further private or public offerings of its securities during the balance of 2025. Management is making efforts to raise further funding to scale up operations and meet its longer-term capital needs. The company continues its focus on improving the design and technological capabilities of its existing SSi Mantra system and further expanding its product offerings.

Management Comments

• The increase in gross profit margin was on account of decreases in raw material prices and improvements in manufacturing processes which resulted in less consumption of raw material from the 2024 quarter to the 2025 quarter.
• The increase in SG&A expense compared to the previous period is primarily due to higher legal and underwriting fees and expenses incurred for business events held during the current period, which were not present in the previous period.
• The company is still in its initial years of revenue generation by way of the sale of its product and has not yet established consistent operational revenue cash flows to meet all its fixed operating costs and hence may continue to incur losses for some time.
• Management of the Company believes that it will be successful in its capital formation and planned expansion of its operating activities, there can be no assurance that the Company will be able to raise additional equity capital or be successful in generating additional revenues and ultimately achieving profitability.

Industry Context

The company operates in the surgical robotics market, which is experiencing increasing awareness of the benefits of robotically assisted surgery, reduced learning curves for robotic surgeons, and a focus on affordability and accessibility, particularly in underserved regions. Its manufacturing base in India provides significant operating cost advantages in terms of quality and cost-effective fabrication, components, outsourced services, and skilled manpower.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company's Indian subsidiary is under review with the Indian Income Tax Department for Assessment Year 2024-25 regarding transfer pricing regulations.
• A Transfer Pricing adjustment of $550,617 was proposed by the TPO, later reduced to $533,281 after partial relief from the Dispute Resolution Panel.
• The company has filed an appeal before the Income Tax Appellate Tribunal (ITAT) on the remaining disputed issues.
• Management believes its position will more likely than not be sustained upon final examination by tax authorities, and no liabilities have been accrued.

Related Party Transactions

• Expenses incurred on behalf of affiliates (Srivastava Robotic Surgery Pvt Ltd, SS International Centre for Robotics Surgery Pvt Ltd, Sudhir Srivastava Medical Innovations Pvt Ltd, Telegnosis Private Limited, Sudhir Prem Srivastava, M.D.).
• Expenses incurred on behalf of the Company (Sudhir Prem Srivastava, M.D., Barry F. Cohen, Dr. Frederic H Moll, Dr. S.P. Somashekhar).
• Stock compensation expenses for related parties (Anup Sethi, Barry F. Cohen, Dr. S.P. Somashekhar, Sudhir Prem Srivastava, M.D., Vishwajyoti P. Srivastava, M.D).
• Consultancy charges and other perquisites for related parties (Anup Sethi, Barry F. Cohen, Vishwajyoti P. Srivastava, M.D, Sudhir Prem Srivastava, Arvind Palaniappan, Naveen Kumar Amar).
• Proceeds from notes issued to Sushruta Pvt Ltd. ($28,000,000 in 9 months 2025, $3,500,000 in 9 months 2024).
• Interest accrued on notes to Sushruta Private Limited ($182,400 in 9 months 2025, $115,597 in 9 months 2024).
• Conversion of notes into common stock by Sushruta Private Limited ($30,164,548 in 9 months 2025).
• Balances receivable/payable with Barry F. Cohen, Sushruta Pvt Ltd., Vishwajyoti P. Srivastava, M.D, Naveen Kumar Amar, Cardio Bahamas, Srivastava Robotic Surgery Pvt Ltd, SS International Centre for Robotics Surgery Pvt Ltd, SSI PTE Singapore, Sudhir Prem Srivastava, M.D., Sudhir Srivastava Medical Innovations Pvt Ltd, Telegnosis Private Limited.
• Dr. Sudhir Prem Srivastava is considered the ultimate beneficial owner for certain balances, with settlement expected on a net basis.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and uncertainty due to the 'going concern' risk, but benefit from strong revenue growth and a reduced nine-month net loss.
• Employees are impacted by stock compensation plans and recent management changes.
• Customers benefit from continued product development and expansion of affordable surgical robotics offerings (SSi Mantra, SSi Mudra instruments).
• Creditors, particularly related parties, bear risk due to the company's reliance on debt financing and ongoing operational losses.

Next Steps

• Raise further funding through private or public offerings during the balance of 2025.
• Scale up operations and meet longer-term capital needs.
• Incur capital expenditure for in-house machining and tooling capacity.
• Continue to finance research and development work in surgical robotics.
• Address and remediate material weaknesses in internal control over financial reporting, including enhancing review processes, engaging external experts, and implementing a comprehensive cloud-based ERP system.
• Continue appeal before the Income Tax Appellate Tribunal (ITAT) regarding transfer pricing adjustment.

Key Dates

Recommendation

While SS Innovations International, Inc. demonstrates impressive revenue growth and a substantial reduction in its nine-month net loss, indicating strong operational performance and market penetration for its surgical robotic systems, the persistent 'going concern' warning and identified material weaknesses in internal controls present significant fundamental risks. The company's continued reliance on related-party financing for working capital, despite a working capital surplus, highlights ongoing liquidity concerns. The uplisting to Nasdaq is a positive step for visibility and potential future capital access, but the underlying financial stability issues warrant caution. A 'hold' recommendation is appropriate for existing investors, acknowledging the operational momentum while advising prudence due to the unresolved financial and governance risks. New investors should approach with extreme caution, awaiting clear signs of sustained profitability and resolution of the going concern and internal control issues.

Keywords

Surgical robotics, SSi Mantra, Medical devices, Healthcare technology, SEC filing, 10-Q, Financial results, Revenue growth, Net loss, Going concern, Internal controls, Nasdaq, India, Medical instruments